Product overview

Name PS-341 [Bortezomib]
Purity >98%
Description Highly potent, selective, reversible and cell permeable proteasome inhibitor
Write Your Own Review
You're reviewing:PS-341 [Bortezomib]
Rate this item:

Images

PS-341 [Bortezomib] product vial image | Hello Bio

Biological Data

Biological description Highly potent, selective and reversible cell permeable inhibitor of the proteasome. Inhibits the chymotrypsin-like and caspase-like peptidase activity of the proteasome. Calpain and cathepsin inhibitor. Autophagy activator. Anticancer compound. Inhibits proliferation and migration of several tumor cell lines with nanomolar potency. Apoptosis inducer.

Solubility & Handling

Solubility overview DMSO (100mM)
Storage instructions +4°C
Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Molecular Weight 384.2
Molecular Formula

C19H25BN4O4

CAS Number 179324-69-7
PubChem identifier 387447
SMILES CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O
InChiKey GXJABQQUPOEUTA-RDJZCZTQSA-N
Appearance White solid

References for PS-341 [Bortezomib]

References are publications that support the biological activity of the product
  • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells

    Hideshima et al (3071-6.) Cancer Res. : 61(7)
  • Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells

    Fribley et al (2004) Mol Cell Biol 24(22) : 9695-704.
  • Development of the proteasome inhibitor PS-341

    Adams et al (2002) Oncologist 7(1) : 9-16.

3 Item(s)